Clinical trials with DC based tumor vaccination in prostate cancer and RCC.

Abbreviations: mat-moDC, mature monocyte derived dendritic cell; imm-moDC, immature monocyte derived dendritic cell; id, intradermal; in, intranodal; il, intralymphatic; sc, subcutaneous; iv, intraveneous; CR, complete response; PR, partial response; MR, mixed response; SD, stable disease; PD, progressive disease; n.d., not done.
*tumor antigen specific immune responses; details on all conducted tests are given in Table S4.
+for prostate cancer trials in which PSA courses were used for response criteria they are displayed if they were combined with radiological criteria; clinical responses are indicated in relation to evaluable patients – additional clinical response information and trials response criteria are given in Table S1.
§PA2024  =  huPAP/GM-CSF fusion protein.
#2 patients received unpulsed and another 2 patients only KLH pulsed DC.
**at least ≥8 weeks from registration.
‡only results of the trial D9902A displayed; the publication also reported on an integrated analysis including the results of the trial D9901 [33].